Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Paolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

David H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Jennifer Scalici, MD, discusses data for IMNN-001plus chemotherapy in advanced ovarian cancer.

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.

Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

The FDA has accepted a sNDA for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia. 

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

Video Series

Clinical

Overview of 3L Treatment Landscape for Colorectal Cancer

Videos

Medical experts discuss the evolving treatment landscape and adverse events associated with 3L colorectal cancer treatment.

Funding supported by Taiho Oncology. Content independently developed by OncLive.

John Strickler, MD, introduces a panel of medical experts who will provide key insights for considerations in the 3L colorectal cancer treatment setting.

Arvind Dasari, MD, MS, illustrates pivotal points of emphasis in choosing the appropriate treatment strategy for a patient receiving 3L treatment for colorectal cancer.

Selecting Optimal 3L Colorectal Cancer Treatment

Medical experts dissect the first patient-specific case and corresponding treatment regimen.

Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

John Strickler, MD, presents the case of a 62-year-old woman with rectal cancer, and Arvind N. Dasari, MD, MS, provides clinical insights on his approach to third-line treatment with regorafenib, highlighting dose strategy and patient education.

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Treatment Considerations With Regorafenib in Colorectal Cancer

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.

Monitoring and AE Management Strategies with Fruquintinib in CRC

Experts on colorectal cancer discuss the treatment decision-making process, highlighting the safety profiles of fruquintinib and regorafenib.

Toxicity Considerations and Treatment Decisions in CRC

Clinical insights on the roles of various members within a multidisciplinary team involved in the care of patients with colorectal cancer.

Multidisciplinary Care for Patients with CRC

The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.

Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 1.Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

EP: 2.Selecting Optimal 3L Colorectal Cancer Treatment

EP: 3.Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

EP: 4.General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

EP: 5.Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

EP: 6.Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

EP: 7.Treatment Considerations With Regorafenib in Colorectal Cancer

EP: 8.Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

EP: 9.FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

EP: 10.Monitoring and AE Management Strategies with Fruquintinib in CRC

EP: 11.Toxicity Considerations and Treatment Decisions in CRC

EP: 12.Multidisciplinary Care for Patients with CRC

EP: 13.Unmet Needs and Future Perspectives in Colorectal Cancer

Latest Conference Coverage